title: [PML-RARα and p21 are key factors for maintaining acute promyelocytic leukemia stem cells survival].
abstract: Tumor stem/progenitor cells are the cells with the characteristics of self-renewal, differentiating to all the other cell populations within tumor, which are also regarded as the source of tumor relapse, drug-resistance and metastasis. As a subtype of acute myeloid leukemia, acute promyelocytic leukemia (APL) represents the target of therapy due to the good response of the oncogenic protein PML-RARα to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This review summarizes the latest research results of APL as follows: (1) there probably are two APL stem/progenitor cell populations within APL, and self-renewal and survival of APL stem/progenitor cells highly depend on PML-RARα expression, cell cycle inhibitor p21, self-renewal associated molecules and chemokines; and (2) ATRA and ATO eradicate APL stem/progenitor cells mainly by PML-RARα degradation, FOXO3A activation and the inhibition of self-renewal-associated signaling pathway of sonic hedgehog. These findings are helpful to improve other tumor therapy.
authors: Department of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors: Fei
authors: F
authors: Ding
authors: Jun-Min
authors: JM
authors: Li
mesh_terms: D002470:Cell Survival; D050759:Cyclin-Dependent Kinase Inhibitor p21; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000166:cytology*; D015514:Oncogene Proteins, Fusion; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
chemical_list: D050759:Cyclin-Dependent Kinase Inhibitor p21; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein